Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12538423 | 0.86 | KMO (0.44) | KMOIDO1MAP4K4TRPV3MAOB | |
| SCHEMBL12538599 | 0.82 | CTSS (0.49) | KMOIDO1KDM4EMEN1KMT2A | |
| SCHEMBL12538116 | 0.80 | RAB9A (0.40) | KDM4EMEN1MAPTKMT2ATRPV3 | |
| SCHEMBL12538473 | 0.79 | TRPV3 (0.49) | MAPTTRPV3 | |
| SCHEMBL12538114 | 0.78 | TRPV3 (0.53) | MAP4K4KDM4ETRPV3ALDH1A1 | |
| SCHEMBL12615570 | 0.77 | TRPV3 (0.83) | TRPV3 | |
| SCHEMBL12537708 | 0.77 | TRPV3 (0.40) | KMOKDM4ETRPV3MAOBALDH1A1 | |
| SCHEMBL12538500 | 0.76 | TRPV3 (0.43) | KMOKDM4EMAPTTRPV3ALDH1A1 | |
| SCHEMBL25392607 | 0.75 | KMO (0.38) | KMOIDO1MAP4K4KDM4EMAPT | |
| SCHEMBL31282190 | 0.75 | KMO (0.38) | KMOIDO1MAP4K4KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012651-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20120245124-A1 | TRPV3 Modulators | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012129491-A1 | TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245124-A1 | TRPV3 Modulators | TRPV3, TRPV2, TRPV1 | KMO 2505/4885IDO1 1407/4885MAP4K4 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.